Taletrectinib

Rami Manochakian: Results of ALNEO Phase 2 Trial at ASCO25

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, posted on X:

“Hot Off The Press, Just presented at ASCO25.

Results of ALNEO phase 2 trial of: Neoadjuvant and Alectinib in potentially resectable stage Ill ALK+ Non-Small Cell Lung Cancer

  • pCR: 12%
  • MPR: 46%
  • ORR: 67%
  • Safety profile consistent with previous studies.”

Rami Manochakian: Results of ALNEO Phase 2 Trial at ASCO25

See also:

ALNEO phase 2 trial ASCO25 cancer non small cell lung cancer OncoDaily Oncology Rami Manochakian